Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
Carcinogenesis. 2010 Sep;31(9):1597-603. doi: 10.1093/carcin/bgq132. Epub 2010 Jun 24.
Variation in genes contributing to the host immune response may mediate the relationship between inflammation and prostate carcinogenesis. RNASEL at chromosome 1q25 encodes ribonuclease L, part of the interferon-mediated immune response to viral infection. We therefore investigated the association between variation in RNASEL and prostate cancer risk and progression in a study of 1286 cases and 1264 controls nested within the prospective Physicians' Health Study. Eleven single-nucleotide polymorphisms (SNPs) were selected using the web-based 'Tagger' in the HapMap CEPH panel (Utah residents of Northern and Western European Ancestry). Unconditional logistic regression models assessed the relationship between each SNP and incident advanced stage (T(3)/T(4), T(0)-T(4)/M(1) and lethal disease) and high Gleason grade (>/=7) prostate cancer. Further analyses were stratified by calendar year of diagnosis. Cox proportional hazards models examined the relationship between genotype and prostate cancer-specific survival. We also explored associations between genotype and serum inflammatory biomarkers interleukin-6 (IL-6), C-reactive protein (CRP) and tumor necrosis factor-alpha receptor 2 using linear regression. Individuals homozygous for the variant allele of rs12757998 had an increased risk of prostate cancer [AA versus GG; odds ratio (OR): 1.63, 95% confidence interval (CI): 1.18-2.25), and more specifically, high-grade tumors (OR: 1.90, 95% CI: 1.25-2.89). The same genotype was associated with increased CRP (P = 0.02) and IL-6 (P = 0.05) levels. Missense mutations R462Q and D541E were associated with an increased risk of advanced stage disease only in the pre-prostate-specific antigen era. There were no significant associations with survival. The results of this study support a link between RNASEL and prostate cancer and suggest that the association may be mediated through inflammation. These novel findings warrant replication in future studies.
基因变异在宿主免疫反应中可能介导炎症与前列腺癌发生之间的关系。染色体 1q25 上的 RNASEL 编码核糖核酸酶 L,是干扰素介导的抗病毒感染免疫反应的一部分。因此,我们在前瞻性医师健康研究中进行了一项嵌套病例对照研究,共纳入了 1286 例病例和 1264 例对照,研究了 RNASEL 变异与前列腺癌风险和进展之间的关系。使用基于网络的“Tagger”在 HapMap CEPH 面板(犹他州具有北欧和西欧血统的居民)中选择了 11 个单核苷酸多态性 (SNP)。条件逻辑回归模型评估了每个 SNP 与新发晚期(T(3)/T(4)、T(0)-T(4)/M(1) 和致命性疾病)和高 Gleason 分级(>/=7)前列腺癌之间的关系。进一步的分析按诊断年份进行分层。Cox 比例风险模型检查了基因型与前列腺癌特异性生存之间的关系。我们还使用线性回归探索了基因型与血清炎症生物标志物白细胞介素 6 (IL-6)、C 反应蛋白 (CRP) 和肿瘤坏死因子-α受体 2 之间的关联。rs12757998 变异等位基因纯合的个体患前列腺癌的风险增加[AA 与 GG;比值比 (OR):1.63,95%置信区间 (CI):1.18-2.25),并且更具体地说,是高级别肿瘤 (OR:1.90,95%CI:1.25-2.89)]。相同的基因型与 CRP(P = 0.02)和 IL-6(P = 0.05)水平升高有关。错义突变 R462Q 和 D541E 仅在前前列腺特异性抗原时代与晚期疾病风险增加有关。与生存无显著关联。这项研究的结果支持 RNASEL 与前列腺癌之间的联系,并表明这种关联可能通过炎症介导。这些新发现值得在未来的研究中复制。